This study was performed to determine the correlation between aldehyde dehydrogenase-1A1 (ALDH1A1) level and tumor shrinkage after chemoradiation in locally advanced rectal cancer. This is a retrospective study of 14 locally advanced rectal cancer patients with long course neoadjuvant chemoradiation. The ALDH1A1 level was measured using ELISA from paraffin embedded tissue. Tumor shrinkage was measured from computed tomography (CT) scan or magnetic resonance imaging (MRI) based on Response Evaluation Criteria in Solid Tumor v1.1 (RECIST v1.1). The mean of ALDH1A1 level was 9.014 ± 3.3 pg/mL and the mean of tumor shrinkage was 7.89 ± 35.7%. Partial response proportion was 28.6%, stable disease proportion was 50% and progressive disease proportion was 21.4%. There was a significantly strong negative correlation (r = -0.890, p < 0.001) between ALDH1A1 and tumor shrinkage. In conclusion, tumor shrinkage in locally advanced rectal cancer after preoperative chemoradiation was influenced by ALDH1A1 level. Higher level of ALDH1A1 suggests decreased tumor shrinkage after preoperative chemoradiation. 
ectal cancer is the third most common malignancy in the world and also in Indonesia. Worldwide, there are 1.2 million new cases of colorectal cancer diagnosed annually with 600,000 death cases each year [1] . Chemoradiation as neoadjuvant therapy before surgery to shrink tumor size is widely accepted as a treatment for locally advanced rectal cancer.
Radiation exposure to rectal cancer cell will increase reactive oxygen species that can alter membrane bilayer and cause lipid peroxidation. The breakdown products of lipid peroxides are mostly aldehydes, which may serve as "oxidative stress second messengers" with prolonged half-life and the ability to diffuse from their site of formation to nucleus, compared to reactive oxygen species (ROS). Cells possess aldehyde dehydrogenase-1 (ALDH1), a family of polyform enzyme, which detoxifies these aldehydes. ALDH1 is located in cytoplasm, mitochondria or nucleus [2] [3] [4] . In addition to its known function to oxidize aldehyde, ALDH1 was also found in cancer stem cell (CSC). In 2007, Ginestieret and co-workers have successfully demonstrated the first isoform of ALDH1 as a marker for R doi: 10.18282/amor.v1.i2. 15 normal and malignant human mammary stem cell and predictor of poor clinical outcome [5] . In the following years, ALDH1 activity would be used successfully as a CSC marker for many cancers including lung, liver, bone, colon, pancreatic, prostate, head and neck, bladder, thyroid, brain, melanoma and cervical [6] . With the exception of one recent study on malignant melanoma, increasing evidence suggests that ALDH1 activity is a universal CSC marker [7] . The role of ALDH1 in rectal cancer is not fully understood. Avoranta et al. have demonstrated the prognostic value of ALDH1 in early rectal cancer that received postoperative adjuvant chemotherapy regimens through immunohistochemistry [8] . This study was in line with other colorectal studies, showing the ALDH1 correlation with 5-FU plus oxaliplatin (FOLFOX) resistance in colorectal cancer [9] . One of the isoforms of ALDH1, such as ALDH1A1, was involved in retinoic acid (RA) cell signaling via RA production by oxidizing all-trans-retinal and 9-cis-retinal. Depending on cellular context, this may lead to cell proliferation, apoptosis and cell cycle arrest. This function, in particular, has been linked to the "stemness" characteristic of cancer stem cell and through a different mechanism, cancer stem cell inherently became more resistant to chemo and radiotherapy [6, 10, 11] . These properties are believed to hold an important role in tumor response after chemoradiation. Several qualitative and semi-quantitative studies using immunohistochemistry showed that the expression of ALDH1A1 in cell cytoplasm have no prognostic significance in rectal cancer, but the expression of ALDH1A1 in stromal and the nucleus is associated with shorter survival [12] . In order to provide additional analysis of the biological relevance of ALDH1A1 in locally advanced rectal cancer, we examined the level of ALDH1A1 using the quantitative method with enzyme-linked immunosorbent assay (ELISA) to determine the correlation between ALDH1A1 level in rectal cancer tissue and tumor shrinkage after preoperative chemoradiation.
Materials and methods

Study design
This retrospective study enrolled locally advanced rectal cancer patients (T3-4 N0/+ M0) who underwent radiation therapy in Cipto Mangunkusumo Hospital from January 2009 to January 2014. Out of 144 patients, only 43 patients were able to complete the long course chemoradiation (46-50 Gy in 23-25 fractions) with concurrent Capecitabine or FOLFOX. Also, only 14 from 43 patients who had a decent formalin fixed-paraffin embedded (FFPE) rectal cancer tissue, base and evaluation CT-scan or magnetic resonance imaging (MRI) were found to be eligible for this study. Only three patients underwent surgery after chemoradiation.
Deparaffinization and protein extraction
The study material consisted of FFPE tissue from a biopsy sample. A section with 25 μm thickness and area 40-100 mm 2 were cut from FFPE blocks. Paraffin was removed by washing with xylene 3 times, followed by serial washing with 100%, 70%, and 40% alcohol and aqua dest mixtures. Tissue was rinsed with phosphate buffered saline (PBS), homogenized in 1:1 PBS and stored overnight at -20°C. After two cycles, freezethaw cycles were performed to break the cell membranes. The homogenates were centrifuged for 5 min at 5000 × g, in 2-8°C. The supernatant was removed and assayed immediately.
Enzyme-linked immunosorbent assay
ALDH1A1 concentration was determined by using Cusabio human retinal dehydrogenase 1 (ALDH1A1). 100 µL of sample supernatant and provided standard were added to each well and incubated for 2 h at 37°C. Subsequently, the liquid layer in each well was removed, and 100 µL biotin antibody were added to each well. The mixture was incubated for 1 h at 37°C. Wells were aspirated and washed 3 times using washing buffer. 100 µL HRP-avidin were added to each well and incubated for 1 h at 37°C. After removing the liquid and 5 times of washings with washing buffer, 90 µL tetramethylbenzidine (TMB) substrate were added to each well and incubated for 15-30 min at 37°C. Then, 50 µL of stop solution were added to each well. Within 5 min, ELISA plates were read in a microplate reader, which was set to 450 nm.
Tumor shrinkage evaluation
Baseline imaging and evaluation after chemoradiation were collected by 5 mm slice CT scan or MRI. The longest tumor diameter from baseline and evaluation were compared and classified using RECIST v1.1 methods [13] . Imaging baseline was done within 4 weeks before chemoradiation, and imaging evaluation was done after 4 weeks upon completion of chemoradiation. The longest diameter of tumor was measured and compared with the baseline and evaluation imaging. Correlation between ALDH1A1 level and tumor shrinkage was analyzed using bivariate (Pearson) correlation with bootstrap. 
Ethics statement
This study was approved by the ethics committee of Medical Faculty, University of Indonesia.
Results
Patient characteristics and outcome
A total of 14 patients were included in our analysis. After preoperative chemoradiation, 4 patients (28.6%) had partial response, 7 patients (50%) with stable disease and 3 patients with progressive disease ( Table 1 ). 
ALDH1A1 and tumor shrinkage
Mean of ALDH1A1 level was 9.014 pg/mL. The mean of the longest tumor diameter before chemoradiation was 4.42 cm and after chemoradiation was 4.09 cm. The mean of tumor shrinkage percentage was 7.89%. There was a significantly strong negative correlation (r = -0.890, p < 0.001) (Figure 1 ) with higher ALDH1A1 indicating a decreased tumor shrinkage response (Tables  2 and 3) . Figure 1 ALDH1A1 level has a significantly strong negative correlation with tumor shrinkage after chemoradiation. r = -0.890 and p < 0.001 
Discussion
This is a quantitative study using ELISA to determine ALDH1A1 level from FFPE rectal cancer tissues. Previous ALDH1 studies on rectal cancer mostly used a semiquantitative method such as immunohistochemistry. The tumor shrinkage was evaluated using RECIST v1.1, which is widely used as a tool to evaluate solid tumor response. The pathological response was unable to be assessed due to low number of operation after chemoradiation. ALDH1A1 has been proposed in association with worse prognosis and response to chemotherapy [12] . The expression of ALDH1A1 in normal crypts and colorectal carcinoma tissues has been previously investigated. Researchers have indicated that cells with ALDH1A1 expression were sparse and limited to the bottom of the normal crypts, where the stem cells or the proliferative cells reside [14] . ALDH1A1 is also known for its capability to differentiate stem cell cancer and non-stem cell cancer [15] . Xu et al. [16] stated the different results with heterogeneous pattern of ALDH1A1 staining between rectal cancer cell and adjacent stromal cell. 32.3% of the samples showed a high expression in cancer cell and low expression in adjacent stromal cell. 48.8% of the samples showed a high expression of ALDH1A1 in adjacent stromal cell. Only 16% showed no difference from cancer cell and adjacent stromal [16] .
Our present study measured the quantitative level of ALDH1A1 from rectal cancer biopsy tissue that contains both cancer cell and adjacent stromal tissue. It was also shown that there was a strong negative and significant correlation between ALDH1A1 level in FFPE rectal cancer tissue with tumor shrinkage after chemoradiation.
Chemoradiation response is lower (28.6%) compared to the previous study by Lim et al. (40.8%) [17] , which may be due to a fewer number of samples in this study. There is a prospect of using ALDH1A1 as a tool to select more suitable locally advanced rectal patients who will undergo preoperative chemoradiation to avoid unnecessary morbidity. A further study with larger sample size is needed to validate it.
Conclusion
ALDH1A1 level in locally advanced rectal cancer tissue is associated with decreased tumor shrinkage response after preoperative chemoradiation.
